
Jul 22, 2014 by Brian Wilson
Why Investors Continue to Flee Aegerion Stock
In theory Aegerion could still reach this peaks sales figure (quite easily) given that there are many more reimbursable HoFH patients out there, but it appears that Amgen’s (AMGN) hugely successful PCSK9 inhibitor evolocumab will dethrone Juxtapid before that happens.
